- for the purpose of securing the company's commitments under the performance based, long-term share programs
The Extraordinary General Meeting of Swedish Orphan Biovitrum AB (publ) on 24 August 2011 resolved - for the purpose of ensuring that the Company can fulfill its commitments under the performance based, long-term share programs 2008-2011 and the CEO share program 2011 (the "Share Programs") - on an authorization for the board to resolve on directed share issues of class C shares. The General Meeting also resolved to authorize the board of directors to resolve on the repurchase of all issued class C shares by an offer directed to all holders of class C shares. Shares issuance and repurchase under these authorizations may be made on one or several occasions until the Annual General Meeting in 2012 and at a price corresponding to the quotient value of the share (approximately SEK 0.55).
The board of directors has resolved to exercise these authorizations for the said purposes by issuing 684,590 class C shares to Carnegie Investment Bank AB, against a cash consideration of approximately SEK 376,000, and by repurchasing of all issued class C shares against payment of the same amount. Subscription of class C shares may take place during the period 27 April - 8 June 2012 and repurchase of the class C shares may be effected during the period 27 April - 19 June 2012.
The class C shares will following the repurchase be converted to common shares in the number that is required to ensure delivery under the Share Programs.
The company currently holds 2,068,534 own class C shares. Subsequently to the share issuance and following the repurchase of class C shares, the number of own class C shares will amount to 2,753,124.
For further information, please contact:
Åsa Stenqvist, Head of Communications
Tel.: +46 8 697 21 88.
Swedish Orphan Biovitrum (Sobi)Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the health of rare disease patients and their families. The product portfolio comprises about 45 marketed products as well as projects in the late clinical phase. Key therapeutic areas are Inflammation and Genetics & Metabolism. In 2011, Sobi had revenues of SEK 1.9 billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com (http://www.sobi.com/).
The information above has been published pursuant to the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 24 April 2012 at 8:45 a.m. CET.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
